Table 5.

Characterisitics of patients and corresponding PDXs

	Clinical history	Prior treatment	Days to initial tumor growth	Cell line generation
TKO-001	PDX from biopsy specimens of hepatic metastasis in a 72-year-old hispanic male	Surgical resection cisplatin and etoposide with good response Platinum sensitive recurrence retreated with platinum/etoposide salvage therapy with irinotecan	335	No
TKO-002	PDX from biopsy of hepatic metastasis from a female white patient	Frontline carboplatin/etoposide with tumor response after two cycles and progression after the fourth cycle Single agent etoposide Topotecan	49	Yes
TKO-003	PDX from bronchoscopic biopsy samples obtained from a paratracheal mass and subcarinal lymph node metastasis in a 71-year-old African American male	Initial diagnosis of limited stage SCLC treated with combined radiation and cisplatin/etoposide. Following recurrence 2 years later of his platinum sensitive disease, he was retreated with carboplatin/etoposide and more recently was treated with topotecan prior to study enrollment	135	No
TKO-004			No growth	No
TKO-005	PDX developed using bronchoscopic biopsy samples obtained from a left lower lung nodule in a 50 year old African American male	Previously treated with combined radiation and cisplatin/etoposide for limited stage SCLC. Patient had disease progression more than 6 months after completion of chemoradiation and had no other systemic therapy prior to coming on this clinical trial when the biopsy was obtained to generate the PDX	103	No
TKO-006			No growth	No
TKO-007			No growth	No
TKO-008	PDX generated using lung biopsy from a 76-year-old male Caucasian patient	Previously treated with carboplatin/etoposide for six cycles. He subsequently received paclitaxel for progressive disease that occurred 4 months after completing frontline therapy	239	No
TKO-009			No growth	No